Влияние ингибиторов рецепторов ангиотензина-неприлизина на ремоделирование миокарда у пациентов с хронической сердечной недостаточностью и фибрилляцией предсердий

Цель. Оценить влияние ингибиторов ангиотензиновых рецепторов и неприлизина на ремоделирование миокарда у пациентов с хронической сердечной недостаточностью и фибрилляцией предсердий. Материалы и методы. В группе из 15 пациентов с сочетанием хронической сердечной недостаточности вследствие дилатационной кардиомиопатии и пароксизмальной формы фибрилляции предсердий проанализирована динамика параметров ультразвуковых структурных и функциональных показателей левого предсердия и левого желудочка сердца на фоне 6-месячной терапии сакубитрил/валсартаном. Результаты. Полученные результаты свидетельствуют о статистически значимом положительном влиянии использования ингибиторов ангиотензиновых рецепторов и неприлизина на параметры ремоделирования левого предсердия, левого желудочка, а также уровни натрийуретических пептидов ANP и NT-pro-BNP. Заключение. Применение АРНИ может являться перспективным в плане лечения и профилактики развития ФП у пациентов с ХСН.

1. Chamberlain AM, Redfield MM, Alonso A, Weston SA, Roger VL. Atrial Fibrillation and Mortality in Heart Failure: A Community Study. Circulation: Heart Failure. 2011;4(6):740–6. DOI: 10.1161/CIRCHEARTFAILURE.111.962688

2. Pedersen OD, Brendorp B, Køber L, Torp-Pedersen C. Prevalence, prognostic significance, and treatment of atrial fibrillation in congestive heart failure with particular reference to the DIAMONDCHF study. Congestive Heart Failure (Greenwich, Conn.). 2003;9(6):333–40. PMID: 14688506

3. Sossalla S, Vollmann D. Arrhythmia-induced cardiomyopathy. Deutsches Aerzteblatt Online. 2018;115(19):335–41. DOI: 10.3238/arztebl.2018.0335

4. Ehrlich JR, Nattel S, Hohnloser SH. Atrial fibrillation and congestive heart failure: specific considerations at the intersection of two common and important cardiac disease sets. Journal of Cardiovascular Electrophysiology. 2002;13(4):399–405. DOI: 10.1046/j.1540-8167.2002.00399.x

5. Thihalolipavan S, Morin DP. Atrial Fibrillation and Congestive Heart Failure. Heart Failure Clinics. 2014;10(2):305–18. DOI: 10.1016/j.hfc.2013.12.005

6. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal. 2016;37(38):2893–962. DOI: 10.1093/eurheartj/ehw210

7. Lee Park K, Anter E. Atrial Fibrillation and Heart Failure: A Review of the Intersection of Two Cardiac Epidemics. Journal of Atrial Fibrillation. 2013;6(1):751. DOI: 10.4022/jafib.751

8. Rivero-Ayerza M, Scholte op Reimer W, Lenzen M, Theuns DAMJ, Jordaens L, Komajda M et al. New-onset atrial fibrillation is an independent predictor of in-hospital mortality in hospitalized heart failure patients: results of the EuroHeart Failure Survey. European Heart Journal. 2008;29(13):1618–24. DOI: 10.1093/eurheartj/ehn217

9. Zafrir B, Lund LH, Laroche C, Ruschitzka F, Crespo-Leiro MG, Coats AJS et al. Prognostic implications of atrial fibrillation in heart failure with reduced, mid-range, and preserved ejection fraction: a report from 14 964 patients in the European Society of Cardiology Heart Failure Long-Term Registry. European Heart Journal. 2018;39(48):4277–84. DOI: 10.1093/eurheartj/ehy626

10. Терещенко С. Н., Романова Н. В., Жиров И. В., Осмоловская Ю. Ф., Голицын С. П. Российский регистр больных хронической сердечной недостаточностью и фибрилляцией предсердий (РИФХСН): клинико-демографические характеристики выборки на момент включения в регистр. Журнал Сердечная Недостаточность. 2016;17(6):418–26. DOI: 10.18087/rhfj.2016.6.2276

11. Prabhu S, McLellan AJA, Walters TE, Sharma M, Voskoboinik A, Kistler PM. Atrial Structure and Function and its Implications for Current and Emerging Treatments for Atrial Fibrillation. Progress in Cardiovascular Diseases. 2015;58(2):152–67. DOI: 10.1016/j.pcad.2015.08.004

12. Quiñones MA, Greenberg BH, Kopelen HA, Koilpillai C, Limacher MC, Shindler DM et al. Echocardiographic predictors of clinical outcome in patients with left ventricular dysfunction enrolled in the SOLVD registry and trials: significance of left ventricular hypertrophy. Studies of Left Ventricular Dysfunction. Journal of the American College of Cardiology. 2000;35(5):1237–44. DOI: 10.1016/S0735-1097(00)00511-8

13. Rossi A, Cicoira M, Zanolla L, Sandrini R, Golia G, Zardini P et al. Determinants and prognostic value of left atrial volume in patients with dilated cardiomyopathy. Journal of the American College of Cardiology. 2002;40(8):1425–30. DOI: 10.1016/S0735-1097(02)02305-7

14. Ristow B, Ali S, Whooley MA, Schiller NB. Usefulness of Left Atrial Volume Index to Predict Heart Failure Hospitalization and Mortality in Ambulatory Patients with Coronary Heart Disease and Comparison to Left Ventricular Ejection Fraction (from the Heart and Soul Study). The American Journal of Cardiology. 2008;102(1):70–6. DOI: 10.1016/j.amjcard.2008.02.099

15. McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR et al. Angiotensin–niprilysin Inhibition versus enalapril in heart failure. New England Journal of Medicine. 2014;371(11):993–1004. DOI: 10.1056/NEJMoa1409077

16. Wang Y, Zhou R, Lu C, Chen Q, Xu T, Li D. Effects of the Angiotensin - Receptor Neprilysin Inhibitor on Cardiac Reverse Remodeling: Meta-Analysis. Journal of the American Heart Association. 2019;8(13):e012272. DOI: 10.1161/JAHA.119.012272

17. Nagueh SF, Bhatt R, Vivo RP, Krim SR, Sarvari SI, Russell K et al. Echocardiographic Evaluation of Hemodynamics in Patients with Decompensated Systolic Heart Failure. Circulation: Cardiovascular Imaging. 2011;4(3):220–7. DOI: 10.1161/CIRCIMAGING.111.963496

18. Bajraktari G, Pugliese NR, D’Agostino A, Rosa GM, Ibrahimi P, Perçuku L et al. Echo- and B-Type Natriuretic Peptide-Guided Follow-Up versus Symptom-Guided Follow-Up: Comparison of the Outcome in Ambulatory Heart Failure Patients. Cardiology Research and Practice. 2018;2018:3139861. DOI: 10.1155/2018/3139861

19. Opasich C. Six-minute walking performance in patients with moderate-to-severe heart failure; is it a useful indicator in clinical practice? European Heart Journal. 2001;22(6):488–96. DOI: 10.1053/euhj.2000.2310

20. Rector TS, Kubo SH, Cohn JN. Patients self-assessment of their congestive heart failure. Part 2: content, reliability and validity of a new measure, the Minnesota living with heart failure questionnaire. Heart failure. 1987;10:198–209

21. Heijman J, Voigt N, Abu-Taha IH, Dobrev D. Rhythm Control of Atrial Fibrillation in Heart Failure. Heart Failure Clinics. 2013;9(4):407–15. DOI: 10.1016/j.hfc.2013.06.001

22. Hohendanner F, Messroghli D, Bode D, Blaschke F, Parwani A, Boldt L-H et al. Atrial remodelling in heart failure: recent developments and relevance for heart failure with preserved ejection fraction: Guest Editorial. ESC Heart Failure. 2018;5(2):211–21. DOI: 10.1002/ehf2.12260

23. Ling L-H, Kistler PM, Kalman JM, Schilling RJ, Hunter RJ. Comorbidity of atrial fibrillation and heart failure. Nature Reviews Cardiology. 2016;13(3):131–47. DOI: 10.1038/nrcardio.2015.191

24. Pandit SV, Workman AJ. Atrial Electrophysiological Remodeling and Fibrillation in Heart Failure. Clinical Medicine Insights: Cardiology. 2016;10(Suppl 1):41–6. DOI: 10.4137/CMC.S39713

25. Schreieck J, Wang Y, Overbeck M, Schömig A, Schmitt C. Altered Transient Outward Current in Human Atrial Myocytes of Patients with Reduced Left Ventricular Function. Journal of Cardiovascular Electrophysiology. 2000;11(2):180–92. DOI: 10.1111/j.1540-8167.2000.tb00318.x

26. Workman AJ, Pau D, Redpath CJ, Marshall GE, Russell JA, Norrie J et al. Atrial cellular electrophysiological changes in patients with ventricular dysfunction may predispose to AF. Heart Rhythm. 2009;6(4):445–51. DOI: 10.1016/j.hrthm.2008.12.028

27. Schmidt C, Wiedmann F, Zhou X-B, Heijman J, Voigt N, Ratte A et al. Inverse remodelling of K2P3.1 K+ channel expression and action potential duration in left ventricular dysfunction and atrial fibrillation: implications for patient-specific antiarrhythmic drug therapy. European Heart Journal. 2017;38(22):1764–74. DOI: 10.1093/eurheartj/ehw559

28. Xu J, Cui G, Esmailian F, Plunkett M, Marelli D, Ardehali A et al. Atrial Extracellular Matrix Remodeling and the Maintenance of Atrial Fibrillation. Circulation. 2004;109(3):363–8. DOI: 10.1161/01.CIR.0000109495.02213.52

29. Akkaya M, Higuchi K, Koopmann M, Damal K, Burgon NS, Kholmovski E et al. Higher Degree of Left Atrial Structural Remodeling in Patients with Atrial Fibrillation and Left Ventricular Systolic Dysfunction: LV Systolic Dysfunction is Related to LA-SRM in AF Patients. Journal of Cardiovascular Electrophysiology. 2013;24(5):485–91. DOI: 10.1111/jce.12090